{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:35:46Z","timestamp":1767591346682,"version":"3.48.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to evaluate serum visfatin levels in treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS) (PwMS) receiving disease-modifying therapy (DMT) and in naive MS patients (nMS), and to investigate their association with clinical characteristics, treatment status, and disease activity, including NEDA-3 status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 45 PwMS under treatment at least 1 year, 20 nMS patients, and 44 age- and sex-matched healthy controls (HC) were included. Clinical and demographic data were recorded. Serum visfatin, lipid profiles, inflammatory markers, and vitamin levels were measured. Visfatin levels were compared not only between treated and naive MS patients but also within the treated group according to NEDA-3 status and treatment type (first-line vs. second-line disease-modifying therapy). Statistical analyses were performed to assess group differences and correlations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Visfatin levels differed significantly across the three groups (Kruskal\u2013Wallis H = 19.701, p &amp;lt; 0.001). Pairwise comparisons revealed significant differences between all groups: the control group had higher visfatin levels than both the nMS (p &amp;lt; 0.001) and PwMS (p = 0.006). The treated group also showed higher visfatin levels compared to the naive MS group (p = 0.014). Among PwMS visfatin levels were lower than in healthy controls (p = 0.006). Among PwMS patients, those meeting the NEDA-3 criteria had lower visfatin levels and EDSS scores compared with non-NEDA patients (p = 0.008 and p = 0.006, respectively). No significant correlation was found between visfatin and relapse count or EDSS. LDL and total cholesterol levels were significantly higher in patients receiving fingolimod.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Across the three groups, visfatin levels differed significantly, with healthy controls showing the highest levels, followed by PwwMS, and the lowest levels observed in nMS patients. Lower serum visfatin levels in stable treated MS patients may reflect reduced inflammatory burden and effective immunomodulation. These findings suggest that visfatin could serve as a potential biomarker for treatment response in MS. Nevertheless, longitudinal studies including larger cohorts of naive patients are needed to clarify visfatin\u2019s regulatory role in MS pathophysiology and its interaction with disease-modifying therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1641260","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:31:37Z","timestamp":1767591097000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum visfatin in multiple sclerosis: distinct profiles in healthy controls, naive patients, and treated RRMS"],"prefix":"10.3389","volume":"16","author":[{"given":"Saltanat","family":"Mert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130brahim","family":"Ac\u0131r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fcmeyra","family":"\u00d6zt\u00fcrk Emre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00fcbra","family":"Balc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edanur","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e76555","DOI":"10.1371\/journal.pone.0076555","article-title":"Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease","volume":"8","author":"Emamgholipour","year":"2013","journal-title":"PloS One"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5114\/ninp.2012.27211","article-title":"Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis","volume":"46","author":"Kraszula","year":"2012","journal-title":"Neurol Neurochir Pol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/1471-2377-13-172","article-title":"Increased leptin and A-FABP levels in relapsing and progressive forms of MS","volume":"13","author":"Messina","year":"2013","journal-title":"BMC Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2012.11.006","article-title":"High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome","volume":"39","author":"Huang","year":"2013","journal-title":"Peptides"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e2705","DOI":"10.1038\/cddis.2017.132","article-title":"Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell Death Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0807581","article-title":"Pre-B cell colony-enhancing factor (PBEF)\/visfatin: a novel mediator of innate immunity","volume":"83","author":"Luk","year":"2008","journal-title":"J Leukoc Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1748","article-title":"Visfatin, an adipocytokine with proinflammatory and immunomodulating properties","volume":"178","author":"Moschen","year":"2007","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077578","article-title":"Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis","volume":"67","author":"Matsui","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-1544","article-title":"Nuclear factor-kappa B induction by visfatin in human vascular endothelial cells: its role in MMP-2\/9 production and activation","volume":"31","author":"Adya","year":"2008","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/j.2040-4603.2017.tb00757.x","article-title":"Regulation and function of extracellular nicotinamide phosphoribosyltransferase\/visfatin","volume":"7","author":"Carbone","year":"2017","journal-title":"Compr Physiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.01.003","article-title":"Elevated visfatin\/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke","volume":"18","author":"Lu","year":"2009","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.899269","article-title":"Plasma levels of cyclooxygenase-2 (COX-2) and visfatin during different stages and different subtypes of migraine headaches","volume":"23","author":"Li","year":"2017","journal-title":"Med Sci Monit"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-3100","article-title":"Pre-B-cell colony-enhancing factor and its clinical correlates with acute lung injury and sepsis","volume":"140","author":"Lee","year":"2011","journal-title":"Chest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2008.09.008","article-title":"Circulating visfatin in chronic obstructive pulmonary disease","volume":"25","author":"Liu","year":"2009","journal-title":"Nutrition"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.046540","article-title":"Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis","volume":"65","author":"Otero","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1038393","article-title":"Multiple sclerosis and obesity: the role of adipokines","volume":"13","author":"Correale","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103825","article-title":"Adipokines in multiple sclerosis: immune dysregulation, neuroinflammation, and therapeutic opportunities","volume":"24","author":"Ghaffary","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1097243","article-title":"Visfatin: a protein secreted by visceral fat that mimics the effects of insulin","volume":"307","author":"Fukuhara","year":"2005","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.665893","article-title":"Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization","volume":"115","author":"Dahl","year":"2007","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.294.5543.870","article-title":"The plasticity of dendritic cell responses to pathogens and their components","volume":"294","author":"Huang","year":"2001","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19930","article-title":"Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis","volume":"113","author":"Jia","year":"2004","journal-title":"J Clin Invest"},{"key":"B22","article-title":"Elevated serum visfatin levels in patients with acute myocardial infarction","volume":"15","author":"Mazaherioun","year":"2012","journal-title":"Arch Iran Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2007.04.007","article-title":"Serum concentration of visfatin in obese women","volume":"56","author":"Zahorska-Markiewicz","year":"2007","journal-title":"Metabolism"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2014.04.008","article-title":"Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis","volume":"57","author":"Kadoglou","year":"2014","journal-title":"Peptides"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2018.1528270","article-title":"Adipokines in multiple sclerosis patients with and without optic neuritis as the first clinical presentation","volume":"48","author":"D\u00fczel","year":"2019","journal-title":"Immunol Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.04.006","article-title":"Investigation of the prognostic value of adipokines in multiple sclerosis","volume":"15","author":"\u00c7oban","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(03)00154-1","article-title":"Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta","volume":"139","author":"Batocchi","year":"2003","journal-title":"J Neuroimmunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103311","article-title":"Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients","volume":"56","author":"Baharnoori","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26168070","article-title":"Evaluation of selected serum adipocytokines in RRMS treated with immunomodulatory second-line drugs","volume":"26","author":"Adamczyk","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114847","article-title":"Pharmacological and physiological roles of adipokines and myokines in metabolic-related dementia","volume":"163","author":"Arjunan","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B31","article-title":"The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalus","volume":"36","author":"Sosvorova","year":"2015","journal-title":"Neuro Endocrinol Lett"},{"key":"B32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0165-5728(91)90073-g","article-title":"Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis","volume":"32","author":"Maimone","year":"1991","journal-title":"J Neuroimmunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-nutr-071811-150746","article-title":"Visfatin\/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology","volume":"32","author":"Dahl","year":"2012","journal-title":"Annu Rev Nutr"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231221415","article-title":"Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: a nationwide cohort study of 2095 patients in Denmark","volume":"30","author":"Framke","year":"2024","journal-title":"Mult Scler"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4274\/BMJ.galenos.2023.2023.6-2","article-title":"Examining biomarker levels in patients diagnosed with multiple sclerosis","volume":"19","author":"Ac\u0131r","year":"2023","journal-title":"Med J Bakirkoy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/2055217319882720","article-title":"HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis","volume":"5","author":"Blumenfeld Kan","year":"2019","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-020-09937-4","article-title":"Lipid profile alterations during fingolimod treatment in multiple sclerosis patients","volume":"15","author":"Rauma","year":"2020","journal-title":"J Neuroimmune Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1641260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:31:38Z","timestamp":1767591098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1641260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2025.1641260"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1641260","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1641260"}}